An Oversupply Of COVID Antibody Treatments? Multiple Monoclonal Products Raise Potential For Errors

 
• By Derrick Gingery
  
Molecular model of antibody taking part in immune defence. Molecule of immunoglobulin, 3D illustration
The US government is ready to begin allocation of Regeneron's casirivimab-imdevimab monoclonal antibody combination, which just received an EUA for use as a COVID-19 treatment. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet